Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women

Exclusion Criteria

• •1. a positive pregnancy test will automatically exclude the volunteer from participation in this study.
• •2. any contraindication for oral contraception use;
• •3. known hypersensitivity to Letrozole and co-administered medications;
• •4. irregular menstrual cycles;
• •5. ultrasonographic evidence of ovarian dysfunction, such as Polycystic Ovary Syndrome (PCOS);
• •6. history of pituitary tumor;
• •7. HIV, HBV, HCV infection;
• •8. vaginal infection;
• •9. abnormal ECG;
• •10. abnormal lab tests for blood profile, liver function and renal function;
• •11. uncontrolled diabetes and blood pressure;
• •12. pregnancy (suspected or diagnosed) or lactation;
• •13. history or suspicion of drug or alcohol abuse;
• •14. history of severe mental disorders;
• •15. participation in an investigational drug trial within the 30 days prior to selection;
• •16. exhibits a disorder that is a contraindication to steroid hormonal therapy, including, for example, the following conditions:
• •* history of, or actual, thrombophlebitis or thromboembolic disorders.
• •* history of, or actual, cerebrovascular disorders.
• •* history of, or actual, myocardial infarction or coronary artery disease.
• •* acute liver disease.
• •* history of, or actual, benign or malignant liver tumors.
• •* history of, or suspected, carcinoma of the breast.
• •* known, or suspected, estrogen-dependent neoplasia.
• •* undiagnosed abnormal vaginal bleeding.
• •* any ocular lesion arising from ophthalmic vascular disease, such as partial or complete loss of vision or defect in visual field.